Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study)
Enregistré dans:
Auteurs principaux: | Dafna Yahav, Benaya Rozen-Zvi, Tiki Mashraki, Alaa Atamna, Haim Ben-Zvi, Erez Bar-Haim, R Rahamimov |
---|---|
Format: | article |
Langue: | EN |
Publié: |
BMJ Publishing Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4d831f93ee1a40e2acc2929792332b0c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Immunogenicity of a BNT162b2 vaccine booster in health-care workers
par: Esther Saiag, et autres
Publié: (2021) -
Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
par: Krzysztof Lukaszuk, et autres
Publié: (2021) -
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
par: Piotr Rzymski, et autres
Publié: (2021) -
Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
par: Elvira Baos, et autres
Publié: (2022) -
Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
par: Serge Goldman, et autres
Publié: (2021)